{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:36:55Z","timestamp":1791059815557,"version":"4.1.0"},"reference-count":28,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,7,22]]},"abstract":"<jats:p>The continued evolution of bacterial resistance to the \u03b2-lactam class of antibiotics has necessitated countermeasures to ensure continued effectiveness in the treatment of infections caused by bacterial pathogens. One relatively successful approach has been the development of new \u03b2-lactam analogs with advantages over prior compounds in this class. The carbapenems are an example of such \u03b2-lactam analogs possessing improved stability against \u03b2-lactamase enzymes and, therefore, a wider spectrum of activity.<\/jats:p>","DOI":"10.1128\/aac.02240-19","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T13:48:50Z","timestamp":1589377730000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":33,"title":["<i>In Vitro<\/i>\n            and\n            <i>In Vivo<\/i>\n            Characterization of Tebipenem, an Oral Carbapenem"],"prefix":"10.1128","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5267-4176","authenticated-orcid":false,"given":"Nicole","family":"Cotroneo","sequence":"first","affiliation":[{"name":"Spero Therapeutics, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Rubio","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A.","family":"Critchley","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Pillar","sequence":"additional","affiliation":[{"name":"Micromyx, Kalamazoo, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Pucci","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025247"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025239"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2017.03.022"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1496821"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.203-207.2001"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02618-18"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2017.1358618"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00284-018-1543-8"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-017-0214-z"},{"key":"e_1_3_2_11_2","first-page":"296","volume-title":"Antibiotics in laboratory medicine","author":"Craig WA","year":"1996","unstructured":"Craig WA, Gudmundsson S. 1996. Postantibiotic effect, p 296\u2013329. In Lorian V (ed), Antibiotics in laboratory medicine. Williams and Wilkins Co, Baltimore, MD."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.suppl_3.13"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00603-19"},{"key":"e_1_3_2_14_2","volume-title":"Handbook of animal models of infection","author":"Zak O","year":"1999","unstructured":"Zak O, Sande MA. 1999. Handbook of animal models of infection. Academic Press, London, United Kingdom."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01783-16"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules21010062"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2009.116"},{"issue":"100","key":"e_1_3_2_18_2","article-title":"Establishment and characterization of UTI and CAUTI in a mouse model","volume":"2015","author":"Conover MS","year":"2015","unstructured":"Conover MS, Flores-Mireles AL, Hibbing ME, Dodson K, Hultgren SJ. 2015. Establishment and characterization of UTI and CAUTI in a mouse model. J Vis Exp 2015(100):e52892.","journal-title":"J Vis Exp"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.252529799"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0600938103"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.58.5.1281-1289.1990"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.7.3999-4006.2005"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02181-18"},{"key":"e_1_3_2_24_2","first-page":"1259","article-title":"In vitro and in vivo activity of tebipenem against ESBL-producing E. coli","volume":"97","author":"Thamlikitkul V","year":"2014","unstructured":"Thamlikitkul V, Lorchirachoonkul N, Tiengrim S. 2014. In vitro and in vivo activity of tebipenem against ESBL-producing E. coli. J Med Assoc Thai 97:1259\u20131268.","journal-title":"J Med Assoc Thai"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2017.1329417"},{"key":"e_1_3_2_26_2","volume-title":"M7-A10: methods for dilution antimicrobial susceptibility tests for bacterial that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. M7-A10: methods for dilution antimicrobial susceptibility tests for bacterial that grow aerobically; approved standard, 10th ed. CLSI, Wayne, PA.","edition":"10"},{"key":"e_1_3_2_27_2","volume-title":"M26-A: methods for determining bactericidal activity of antimicrobial agents: approved guideline","author":"National Committee for Clinical Laboratory Standards","year":"1999","unstructured":"National Committee for Clinical Laboratory Standards. 1999. M26-A: methods for determining bactericidal activity of antimicrobial agents: approved guideline. NCCLS, Wayne, PA."},{"key":"e_1_3_2_28_2","volume-title":"M11-A8: methods for antimicrobial susceptibility testing of anaerobic bacteria","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. M11-A8: methods for antimicrobial susceptibility testing of anaerobic bacteria, 9th ed. CLSI, Wayne, PA.","edition":"9"},{"key":"e_1_3_2_29_2","volume-title":"M100: performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2019","unstructured":"Clinical and Laboratory Standards Institute. 2019. M100: performance standards for antimicrobial susceptibility testing, 29th ed. CLSI, Wayne, PA.","edition":"29"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02240-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02240-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:39:55Z","timestamp":1645479595000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02240-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,7,22]]}},"alternative-id":["10.1128\/AAC.02240-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.02240-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]},"assertion":[{"value":"2019-11-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02240-19"}}